Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
13 March 2014Website:
http://www.galmedpharma.comNext earnings report:
01 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 27 Jun 2024 23:39:06 GMTDividend
Analysts recommendations
Institutional Ownership
GLMD Latest News
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
What type of business is Galmed Pharmaceuticals?
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
What sector is Galmed Pharmaceuticals in?
Galmed Pharmaceuticals is in the Healthcare sector
What industry is Galmed Pharmaceuticals in?
Galmed Pharmaceuticals is in the Biotechnology industry
What country is Galmed Pharmaceuticals from?
Galmed Pharmaceuticals is headquartered in Israel
When did Galmed Pharmaceuticals go public?
Galmed Pharmaceuticals initial public offering (IPO) was on 13 March 2014
What is Galmed Pharmaceuticals website?
https://www.galmedpharma.com
Is Galmed Pharmaceuticals in the S&P 500?
No, Galmed Pharmaceuticals is not included in the S&P 500 index
Is Galmed Pharmaceuticals in the NASDAQ 100?
No, Galmed Pharmaceuticals is not included in the NASDAQ 100 index
Is Galmed Pharmaceuticals in the Dow Jones?
No, Galmed Pharmaceuticals is not included in the Dow Jones index
When does Galmed Pharmaceuticals report earnings?
The next expected earnings date for Galmed Pharmaceuticals is 01 July 2024